Summary Lecture Gout/Glaucoma Learning Outcomes Predict the activity of a drug based on its structure & physiochemical properties Demonstrate an understanding.

Slides:



Advertisements
Similar presentations
1 Oxypurinol for Gout Arthritis Drugs Advisory Committee June 2, 2004 Cardiome Pharma Corp Vancouver, BC Canada.
Advertisements

N ON - STEROIDAL ANTI - INFLAMMATORY DRUGS. BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF.
Anti-Inflammatory & Immunosuppressive Drugs 2
SUA
TXF Caveat on urate levels Serum uric acid level may be normal at the time of an acute attack. Normal level does not rule out gout. May be better.
Noha Mahmoud Lecturer of Clinical Pharmacy. Course Description This course is one credit hour course given during level 1. It gives idea about pharmacy,
A 42 year old mother of two, Mrs Jan Jones comes into the pharmacy to fill a repeat prescription for a Ventolin Inhaler..
RATIONAL Prescribing & Prescription Writing Dr Arif Hashmi.
Drug Hypersensitivity. Common drug reactions in all patients include overdose, side effects, secondary indirect effects, ​ and drug interactions. Hypersensitivity.
Prepared by : Tamara Odeh Diana Jawhari Supervised by : Dr. Ola Ayesh.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 74 Drug Therapy of Gout.
Pharmacotherapy in the Elderly Paola S. Timiras May, 2007.
Pharmacotherapy in the Elderly Judy Wong
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
Gout: Its not all crystal clear Robert L. Wortmann, M.D. Department of Internal Medicine The University of Oklahoma College of Medicine, Tulsa.
1 Uric acid and Gout James Witter MD, PhD Arthritis Advisory Meeting June 2, 2004.
Familial metabolic disease Characterized by : Acute arthritis Uric stones in the kidneys Hyperuricemia.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
GOUT. OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe treatment of acute gouty arthritis Describe.
MEDICINAL CHEMISTRY- III introduction Wed. 2/ 5/ 1432H Prof. Dr. Wafaa Zaghary PHC 426.
GOUT. By Prof. Azza El- Medany Dr. Osama Yousf OBJECTIVES At the end of lectures students should : Define gout Describe outlines of treatment Describe.
Anti-Inflammatory & Immunosuppressive Drugs 2
GOUT TREATMENT. Gout prevalence doubled over the last 20 yrs. Factors? - longevity - diuretic use - low dose ASA - obesity - end stage renal disease -
Mrs Kearns (78 y.o) asks for an antihistamine. She tells you that she used to use Teldane® when she last had this problem.
A 34 year old male, Tom enters your pharmacy with his partner, Phil and asks for a cough medicine.
N ON - STEROIDAL ANTI - INFLAMMATORY DRUGS. OBJECTIVES At the end of the lecture the students should : Define NSAIDs Describe the classification of this.
Social Pharmacy Lecture no. 8 Rational prescribing guidelines.
Introduction to Pharmacotherapy Ghada A Bawazeer. MSc, PharmD. BCPS King Saud University-College of Pharmacy Sept
GOUT.
Orientation to Pharmacology
Clinical Case #6 By Chen, chun-Yu (Kim) Chen, I -chun (Afra) Chen, I -chun (Afra)
Four Stages of Gout  Asymptomatic hyperuricemia Elevated levels of uric acid in the blood but no other symptoms Does not require treatment  Acute gout/Acute.
TAP PHARMACEUTICAL PRODUCTS INC. June 2, Arthritis Drugs Advisory Committee TAP Pharmaceutical Products Inc. June 2, 2004.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 17 Nonopioid Analgesics: Salicylates and Nonsalicylates.
Gout Familial metabolic disease characterized by : Acute arthritis Uric acid stones in the kidneys Hyperuricemia.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 8 Cephalosporins.
Critical Appraisal of an Article on HARM. Clinical Question Is there potential harm after administering allopurinol in patients with gout and azotemia?
Quality Education for a Healthier Scotland Pharmacy Pharmaceutical Care Planning Vocational Training Scheme: Level = Stage 2 Arlene Shaw Specialist Clinical.
Gout. The most common cause of inflammatory arthritis in US adults (3.9% of Americans; approx. 8.3 million people; ) Prevalence is greater in.
Table of Contents.  Introduction to Pharmacology Go Go  Drugs Go Go.
“Journey of a Drug” From Test Tube TO Prescribing Physician.
Single Competency Framework for Prescribers National Prescribing Centre (2012)
Introduction to Pharmacology Yacoub Irshaid MD, PhD, ABCP Department of Pharmacology.
Manufacturer: AstraZeneca FDA Approval Date: December 22, 2015
Pharmacokinetics: Digoxin Allie Punke
Non-steroidal anti-inflammatory drugs
Gout Pharmacotherapies Joseph Kitzmiller MD PhD FCP 5086 Graves Hall Assistant Professor – Biological Chemistry & Pharmacology
Meet & Greet. Welcome Objectives: 1. Review the core terminology used in pharmacology. 2. Discuss the features of the “perfect” drug. 3. Examine the.
Be Aware Of Various Gout Treatments. Gout is a painful condition caused by a rise in the uric acid level in the blood. The uric acid that accumulates.
Gout Ashley Guzman Primary Care I: Acute and Chronic Health Problems
OBJECTIVES and METHODOLOGY
Gout.
Eucrisa™ - Crisaborole
Cyclooxygenase Inhibitors: Nonsteroidal Anti-Inflammatory Drugs and Acetaminophen 1.
Introduction to pathology
Factors Affecting Drug Activity
Drug Therapy of Gout 1.
GOUT.
Antiuricaemic drugs Dr A.W Olusanya.
Glaucoma.
Gout Management.
The ultimate goal of today’s presentation is to be able to understand the common factors/themes occurring in elderly medication incidents as well.
Medication Nonadherence in Gout
Treat to Target in Gout.
Figure 1 Schematic comparison of expected
CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.
PROSES TERAPI DAN PERMASALAHANNYA
pain management Lecture headlines :
Presentation transcript:

Summary Lecture Gout/Glaucoma

Learning Outcomes Predict the activity of a drug based on its structure & physiochemical properties Demonstrate an understanding of how the physical & chemical properties of a drug determine its pharmacology,toxicology,bioavailability and behaviour in formulations Identify typical example of drugs which are used to restore physiological functions in gout & glaucoma Describe the mechanism of therapeutic action of a selected drug at the molecular,cellular,organ system and whole body levels Describe the common adverse effects of a selected drug & their mechanism of production

Learning Outcomes Demonstrate an understanding of basic metabolism in relation to drugs & efficacy & safety in relation to the treatment of disease and/or maintenance of health Have an awareness of the risk factors & prevalence of gout & glaucoma so as to identify & refer presentations in the pharmacy appropriately

Learning Outcomes Demonstrate an understanding of the clinical & therapeutic principles of treatment of gout & glaucoma Be aware of the pharmacological & non-pharmacological aspects of managing patients with gout & glaucoma

Inflammation Be aware of the cell types involved in inflammation Be aware of the inflammatory mediators Understand the multiple roles of the prostanoids

Allergy Understand the different grades & associated symptoms of allergy Classification of allergic and anaphylactic reactions Types of hypersensitivity Role of IgE Delayed reactions

Allergy Be familiar with appropriate treatments for allergy Understand the cross-reactivity that may exist between sulfonamide antibiotics and other sulfonamide drugs Be familiar with commonly use drugs containing a sulfonamide moiety

Non-selective & selective COX-2 inhibitors Understand the role COX-1 & COX-2 play in the physiological & pathophysiological process of inflammation Be familiar with the arachidonic acid cascade

Selective COX-2 Inhibitors Understand the clinical & molecular differences between a non-selective & selective COX-2 inhibitor Understand the how binding by NSAIDs,COX-1 & COX-2 in the arachidonic acid cascade allows pharmacological targeting due to structural differences

Gout Understand the clinical features of gout Be familiar with serum urate concentrations for hyperuricaemia in males & females Understand the difference between uric acid & urate

Gout Understand the causes of hyperuricaemia Be aware of the risk factors of gout Knowledge of which medications may be predisposing to causing gout

Treatment of gout Knowledge of medications to treat & avoid in the acute attack of gout Be aware of the revised dosing recommendations for colchicine in acute gout When to avoid or reduce the dose of NSAID’s or colchicine & possible drug interactions

Maintenance of gout Urate lowering drugs available Role of xanthine oxidase Dose limitations in renal impairment Understand the rationale behind separating the treatment of acute attacks from introducing urate lowering measures Knowledge of correctable factors to treat

Glaucoma Understand the relevance of elevated intraocular pressure in the diagnosis of glaucoma Pathological features Types of glaucoma Risk factors

Treatments available to manage glaucoma For each of the different classes of eye drops to treat elevated IOP be familiar with their mechanism,efficacy,order of treatment,precautions & contraindications & interactions Understand the need for simplified dosing regimes,individualised education to improve adherence & reduce the risk of blindness

Use of eye drops Be able to instruct the patient on the correct instillation of eye drops How to minimise microbial contamination How to minimise side effects